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797 Video-assisted bilateral pulmonary vein isolation and left atrial appendage
exclusion for atrial fibrillation
Randall K. Wolf, MD, E. William Schneeberger, MD, Robert Osterday, PA, Doug Miller, MED,
Walter Merrill, MD, John B. Flege, Jr, MD, and A. Marc Gillinov, MD, Cincinnati and
Cleveland, Ohio
VATS bilateral epicardial pulmonary vein isolation with excision of the left atrial appendage is
a promising new curative treatment for AF.
803 Surgical ablation of atrial fibrillation with off-pump, epicardial, high-
intensity focused ultrasound: Results of a multicenter trial
Jean Ninet, MD, Xavier Roques, MD, Rainald Seitelberger, MD, Claude Deville, MD,
Jose Luis Pomar, MD, Jacques Robin, MD, PhD, Olivier Jegaden, MD, Francis Wellens, MD,
Ernst Wolner, MD, Catherine Vedrinne, MD, PhD, Roman Gottardi, MD, Javier Orrit, MD,
Marc-Alain Billes, MD, Drew A. Hoffmann, PhD, James L. Cox, MD, and
Gerard L. Champsaur, MD, Lyon and Bordeaux, France; Vienna, Austria; Barcelona, Spain;
Aalst, Belgium; Sunnyvale, Calif; and St Louis, Mo
In 103 patients entered in a prospective multicenter study, atrial fibrillation (permanent in 74%)
was concomitant to structural heart disease requiring surgical therapy. Epicardial beating-heart
ablation with high-intensity focused ultrasound during a 10-minute automatic algorithm to
isolate the pulmonary veins was safe and cured 85% of the global population at the 6-month
follow-up visit.
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810 A randomized, double-blind, placebo-controlled pilot trial of
triiodothyronine in neonatal heart surgery
Andrew S. Mackie, MD, SM, Karen L. Booth, MD, Jane W. Newburger, MD, MPH,
Kimberlee Gauvreau, ScD, Stephen A. Huang, MD, Peter C. Laussen, MBBS,
James A. DiNardo, MD, Pedro J. del Nido, MD, PhD, John E. Mayer, Jr, MD,
Richard A. Jonas, MD, Ellen McGrath, RN, Jodi Elder, RN, and
Stephen J. Roth, MD, MPH, Boston, Mass
We performed a randomized, double-blind, placebo-controlled trial of T3 supplementation in
neonates after cardiac surgery. T3 supplementation resulted in more rapid achievement of a
negative fluid balance and higher systolic blood pressures in the early postoperative period. No
adverse events were attributed to T3 administration.
817 Surgical treatment of giant coronary artery aneurysm
Dianyuan Li, MD, Qingyu Wu, MD, Lizhong Sun, MD, Yunhu Song, MD, Wei Wang, MD,
Shiwei Pan, MD, Guohua Luo, MD, Yongmin Liu, MD, Zhitao Qi, MD, Tianfu Tao, MD,
Jian-Zhong Sun, MD, and Shengshou Hu, MD, Beijing, The People’s Republic of China, and
Philadelphia, Pa
Giant coronary artery aneurysm is extremely uncommon. Of 30,268 patients undergoing heart
surgery at one institution, only 6 were operated on for giant coronary artery aneurysm, all
successfully. Five cases were congenital and associated with coronary artery fistula; the other
was caused by atherosclerosis. Optimal surgical management is individual.
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